Participating Companies

Angiocrine Bioscience
(Pri­vate) De­vel­op­ing tech­nolo­gies out of Weill Cor­nell fo­cused on re­gen­er­a­tion of lungs, ten­dons, car­ti­lage, and liv­er as well as dis­cov­ery pro­grams for other tis­sue types. First gen­er­a­tion pro­grams are au­tol­o­gous ge­net­i­cal­ly-mod­i­fied prod­ucts, de­signed for fast en­try in­to clin­ic and com­mer­cial­iza­tion with a pro­pri­e­tary man­u­fac­tur­ing sys­tem. [more in­for­ma­tion]
Columbia University
Colum­bia Uni­ver­si­ty is one of the world's most im­por­tant cen­ters of re­search and a dist­inc­tive and distin­guished learn­ing en­vi­ron­ment. [more in­for­ma­tion]
Dana Farber Cancer Institute
[more in­for­ma­tion]
Jefferson University & Hospitals
[more in­for­ma­tion]
Kiadis Pharma N.V. [KDS-AMS]
NK-cell plat­form ad­min­is­tered as ad­junct I-O on top of HSCT. Launched FIH POC trial in r/r AML pa­tients (Feb 2020); set to launch ad­di­tio­n­al HSCT trial lat­er in 2020 w/in­ter­im da­ta exp 2021. Pre­sent­ing new da­ta on ex-vi­vo FC21 ex­pand­ed NK-cell ther­a­py in 13 pa­tients at EBMT in 2020. Estab­lished POC in 37 pa­tients to­tal. [more in­for­ma­tion]
Lineage Cell Therapeutics Inc. [LCTX] $369 MM MCap
Cell ther­a­py com­pany with 3 cl­ni­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]
NeuroRx
Lead­ing Re­lief Ther­a­peu­tics Ph 2 trial of Avip­tadil to treat COVID-19 in­duced ARDS in the US. In Phase 3 with read­out ex­pect­ed mid-Jan­uary 2021. Al­so de­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. NRX-101 is in Ph 2b/3 de­vel­op­ment, (Break­through Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for Se­vere Bipo­lar De­pres­sion in pts w Acute Sui­ci­dal Idea­tion and Be­havior. [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
Rev­enue gen­er­at­ing with marine-de­rived and nov­el MoA on­col­o­gy prod­ucts. Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized with di­rect sales-force in EU and part­n­er­ship in US with Janssen. Signed li­cens­ing agree­ment with Jazz Phar­ma for lur­binecte­din in the US - up­front pay­ment of $200M, $100mm on ap­pro­val and up to $550M sales mile­s­tones. [more in­for­ma­tion]
Targovax [TRVX]
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]
University of British Columbia
The pri­mary goal of the en­dow­ment is to pro­vide fi­nan­cial re­turns to sup­port the uni­ver­si­ty's aca­dem­ic mis­sion and to fur­ther UBC's vi­sion to cre­ate a learn­ing en­vi­ron­ment that fos­ters pos­i­tive glob­al ci­t­izen­ship. The goal of the UBC en­dow­ment is to sup­port the uni­ver­si­ty's aca­dem­ic mis­sion in per­pe­tu­i­ty. [more in­for­ma­tion]
White & Case LLP
The firm’s life sci­ences ca­pa­bil­i­ties span strate­g­ic pa­tent counsel­ing, com­plex li­cens­ing and col­lab­o­ra­tion agree­ments, cap­i­tal mar­kets and M&A in the US, EU and glob­al­ly. The firm has been help­ing life sci­ences ac­cess the cap­i­tal mar­kets in this chal­leng­ing time, most re­cent­ly rep­re­sent­ing the un­der­writ­ers in this week’s suc­cess­ful $125M equi­ty of­fer­ing by Ku­ra On­col­o­gy. [more in­for­ma­tion]